Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROLINGUAL vs ISMO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is converted to nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP levels in vascular smooth muscle. This leads to dephosphorylation of myosin light chains, causing vasodilation. It predominantly dilates venous capacitance vessels, reducing preload, and to a lesser extent dilates arterioles, reducing afterload.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.
Acute relief of an angina pectoris attack,Prophylaxis of angina pectoris before activities that may provoke an attack (off-label)
Prevention of angina pectoris due to coronary artery disease,Off-label: Treatment of acute angina (immediate-release forms)
1 to 2 sprays (0.4 mg/spray) sublingually at onset of angina, may repeat every 5 minutes up to 3 doses; prophylactic use: 1 spray 5-10 minutes before activity.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
2-3 minutes for sublingual nitroglycerin; rapid decline due to extensive first-pass metabolism and high clearance (30-40 L/min). Clinical context: extremely short half-life necessitates continuous or frequent dosing for sustained effect.
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Nitroglycerin is extensively metabolized in the liver by glutathione-S-transferases and in vascular smooth muscle by mitochondrial aldehyde dehydrogenase (ALDH2), producing dinitrate metabolites (1,2- and 1,3-glyceryl dinitrate) and mononitrates.
Primarily metabolized in the liver by denitration; minor metabolism via glucuronidation. Metabolites are inactive.
Renal (primarily as glucuronide conjugates and denitrated metabolites): ~60-80%; Fecal: ~20-40%; Biliary: negligible. Less than 1% excreted unchanged.
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
~60% bound, primarily to albumin; low affinity, allowing rapid equilibration with tissues.
Approximately 30% bound to plasma proteins, primarily albumin.
~3 L/kg (0.1-0.2 L/kg for parent drug; larger due to extensive tissue distribution including vascular smooth muscle). High Vd reflects extensive uptake into vessel walls and other tissues.
Vd is 0.6-0.9 L/kg, indicating distribution into total body water. Higher Vd may be observed in patients with heart failure.
Sublingual: ~40-60% (avoiding first-pass hepatic metabolism); Oral: <1% (extensive presystemic clearance by hepatic glutathione-organic nitrate reductase).
Oral: 90-100% (sustained-release formulations). Sublingual: high but variable; generally effective due to extensive absorption.
No dose adjustment required for any GFR level.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose to 10 mg twice daily due to potential accumulation of active metabolite.
Child-Pugh A: no adjustment; Child-Pugh B: consider dose reduction (e.g., 1 spray); Child-Pugh C: avoid use or use extreme caution with reduced dose.
No dose adjustment in Child-Pugh A or B. For Child-Pugh C, reduce dose to 10 mg twice daily and monitor for hypotension.
Not established in pediatric patients for sublingual spray; avoid use in children.
Safety and efficacy not established; no standard dosing recommendations.
Start with lower dose (1 spray) due to increased sensitivity and risk of hypotension.
Start at 10 mg twice daily with gradual titration based on tolerance and renal function. Monitor for hypotension and dizziness.
Do not use NITROLINGUAL with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) or soluble guanylyl cyclase (s GC) stimulators (e.g., riociguat), as severe hypotension, syncope, or myocardial ischemia can occur.
Do not use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension: May cause severe hypotension, especially in volume-depleted patients or those with low systolic blood pressure.,Headache: Common and may be severe; tolerance may develop.,Tolerance: Continuous or frequent use may lead to tolerance, requiring nitrate-free intervals.,Abrupt withdrawal: May precipitate angina; taper if discontinuing long-term therapy.,Hypertrophic cardiomyopathy: May worsen outflow obstruction.,Increased intracranial pressure: Use cautiously in patients with elevated intracranial pressure (e.g., cerebral hemorrhage).
Hypotension and reflex tachycardia may occur,Caution in patients with volume depletion or hypotension,May cause headaches; tolerance may develop with prolonged use,Abrupt withdrawal may increase angina frequency
Hypersensitivity to nitroglycerin or any component of the formulation,Concurrent use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) or s GC stimulators (riociguat),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis, cardiac tamponade, restrictive cardiomyopathy,Acute myocardial infarction with low filling pressure (e.g., right ventricular infarction)
Concurrent use of PDE-5 inhibitors,Severe anemia,Closed-angle glaucoma,Hypersensitivity to isosorbide mononitrate or nitrates,Acute myocardial infarction with low filling pressures
No specific food interactions. Avoid alcohol, which can exacerbate hypotension. Maintain adequate hydration.
Alcohol may enhance hypotension risk. Avoid high-fat meals if extended-release formulation, as they may affect absorption. No other significant food interactions.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin caused decreased fetal weight and increased fetal resorptions at doses 50 times the human dose. Risk cannot be ruled out; use only if clearly needed. No known teratogenicity in first trimester, but caution in third trimester due to maternal hypotension risk.
ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate human studies exist. Use only if potential benefit justifies risk. First trimester: Theoretical risk of hemodynamic effects; avoid unless necessary. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; monitor fetal heart rate. Peripartum: May exacerbate uterine relaxation and postpartum hemorrhage if used near delivery.
Nitroglycerin is excreted in human milk in small amounts. M/P ratio unknown. No adverse effects reported in breastfeeding infants. Caution when administered to nursing women.
Excretion into human milk is unknown. Due to risk of infant methemoglobinemia and hypotension, caution is advised. M/P ratio: Not available. American Academy of Pediatrics considers nitrate derivatives compatible with breastfeeding, but monitor infant for cyanosis and lethargy.
No specific dose adjustment recommended for pregnancy. Use lowest effective dose due to increased plasma volume and clearance. Monitor for hypotension, which may be more pronounced in pregnancy. Titrate based on clinical response.
No specific dose adjustments for ISMO in pregnancy are established due to lack of pharmacokinetic studies. However, pregnancy-induced hemodynamic changes (increased plasma volume, cardiac output) may reduce efficacy; consider dose titration based on clinical response. Avoid doses >60 mg/day to minimize hypotensive risk. Use immediate-release formulations for flexible dosing if needed.
NITROLINGUAL (nitroglycerin sublingual spray) is first-line for acute angina. Administer 1-2 sprays at onset of chest pain; may repeat every 5 minutes up to 3 doses. Avoid in patients with severe hypotension (SBP <90 mm Hg), right ventricular infarction, or concomitant use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) within 24-48 hours. Monitor for orthostatic hypotension; patient should sit or lie down during administration. The spray is absorbed via oral mucosa; do not inhale or swallow. Onset: 1-3 minutes; duration: 30-60 minutes. Do not shake canister; prime before first use or if not used for >6 weeks.
ISMO (isosorbide mononitrate) is a nitrate used for angina prophylaxis, not for acute attacks. Tolerance develops with sustained use; maintain a 10-12 hour nitrate-free interval to prevent tolerance. Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. Contraindicated in severe anemia, increased intracranial pressure, or hypertrophic obstructive cardiomyopathy. Discontinue if blurred vision or dry mouth occurs.
Use 1-2 sprays under or on the tongue at first sign of chest pain.,Do not shake the canister; hold it upright and spray onto or under the tongue.,Avoid swallowing or inhaling the spray; let it absorb through the oral mucosa.,Wait 5 minutes after the first dose; if chest pain persists, repeat up to 3 doses total.,If pain is not relieved after 3 doses, seek emergency medical help immediately.,Do not take with erectile dysfunction medications (e.g., sildenafil, tadalafil) within 24-48 hours.,Sit or lie down when using the spray to prevent dizziness or fainting.,Store at room temperature away from heat; do not freeze. Check expiration date.,Prime the spray before first use (spray 5 times into air) or if not used for 6 weeks (spray once).,Common side effects: headache, dizziness, flushing, low blood pressure.
Take as prescribed to prevent angina; do not use for acute attacks.,May cause headache, dizziness, or hypotension; rise slowly from sitting.,Avoid taking erectile dysfunction drugs (e.g., sildenafil, tadalafil) as severe blood pressure drop can occur.,Do not stop abruptly to avoid rebound angina.,Store in original container away from light and moisture.
No interactions on record
"Bosentan, a dual endothelin receptor antagonist and an inducer of CYP3A4 and CYP2C9, reduces systemic exposure to vismodegib, a Hedgehog pathway inhibitor primarily metabolized by CYP3A4. This interaction leads to decreased serum concentrations of vismodegib, potentially diminishing its antitumor efficacy in patients with advanced basal cell carcinoma. Concomitant use may require vismodegib dose adjustment or alternative therapies to avoid therapeutic failure."
"Vismodegib inhibits CYP3A4, which is the primary enzyme responsible for metabolizing nilotinib. Concomitant administration may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, torsades de pointes, hepatotoxicity, and myelosuppression. Clinical vigilance is warranted due to the narrow therapeutic index of nilotinib."
"Vismodegib, a hedgehog pathway inhibitor, is a moderate inhibitor of CYP2C9, the primary enzyme responsible for metabolizing tolbutamide. Concomitant use can significantly decrease tolbutamide clearance, leading to elevated plasma concentrations and prolonged hypoglycemic effects. This increases the risk of severe hypoglycemia, especially in diabetic patients, and may require dose adjustment of tolbutamide."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROLINGUAL vs ISMO, answered by our medical review team.
NITROLINGUAL is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP levels in vascular smooth muscle. This leads to dephosphorylation of myosin light chains, causing vasodilation. It predominantly dilates venous capacitance vessels, reducing preload, and to a lesser extent dilates arterioles, reducing afterload.. ISMO is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROLINGUAL and ISMO depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROLINGUAL is: 1 to 2 sprays (0.4 mg/spray) sublingually at onset of angina, may repeat every 5 minutes up to 3 doses; prophylactic use: 1 spray 5-10 minutes before activity.. The standard adult dose of ISMO is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROLINGUAL and ISMO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROLINGUAL is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin caused decreased fetal weight and increased fetal resorptions at doses 50 times th. ISMO is classified as Category C. ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.